rs20575

This case-control study of 160 Egyptian patients with HCV-related liver disease evaluated two TRAIL receptor 1 (DR4) polymorphisms as risk factors for hepatocellular carcinoma (HCC). The C626G variant (rs20575) showed a significant association with HCC risk (OR=2.01 for C allele carriers, p=0.003), while A683C (rs20576) alone did not. The combined haplotype of C allele at rs20575 and A allele at rs20576 showed substantially increased HCC risk (OR=2.85, p>0.001).

Turkish case-control study examining TRAIL and TRAIL-DR4 gene polymorphisms in gastric cancer. Compared TRAIL C1595T (rs1131580) and TRAIL-DR4 C626G (rs20575) genotype frequencies between 50 gastric cancer patients and 163 healthy controls. No significant association found between either polymorphism and gastric cancer risk (p>0.256, p>0.189) or clinical parameters including tumor stage, lymph node involvement, distant metastasis, and perineural invasion. Serum TRAIL levels were also not significantly different between groups (p>0.33).